Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 16, 04 December 2023
Open
Access | Article
Evaluation of gefitinib based on indicators of targeted drugs
* Author to whom correspondence should be addressed.
Abstract
In the context where lung cancer poses a serious threat to human health, gefitinib, as a small molecule drug targeting the Epidermal Growth Factor Receptor (EGFR), has attracted widespread attention for its application in the treatment of Non-Small Cell Lung Cancer (NSCLC). Based on commonly utilized synthetic routes, an investigation into various resources led to the proposal of new suggestions for the synthesis of gefitinib. These suggestions have the potential to make the synthesis of gefitinib more efficient, straightforward, and compliant with the principles of green chemistry. Gefitinib shows therapeutic effects in certain specific cases of autoimmune diseases, but whether it can serve as a treatment drug still requires further clinical studies. Resistance to gefitinib is associated with genetic mutations. Such mutations weaken the binding ability of gefitinib to EGFR, ultimately leading to enhanced survival capabilities of mutated NSCLC cells. As treatment progresses, the emergence of resistance presents challenges in therapy. It is hoped that alternative means can be employed to improve treatment efficacy, prolong overall survival (OS), and mitigate the side effects associated with the use of gefitinib.
Keywords
Gefitinib, Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor, Synthetic Routes, Tyrosine Kinase Inhibitor
References
1. Siegel R L, Miller K D, Fuchs H E and et al. 2022 CA. Cancer J. Clin. 72(1) 7–33
2. Remark R, Becker C, Gomez J E, and et al. 2015 Am. J. Respir. Crit. Care Med. 191(4) 377-390
3. Pikor L A, Ramnarine V R, Lam W L, and et al. 2013 Lung Cancer Amst. Neth. 82(2) 179–189
4. Mansour M A, Abbas S, Abdel-Rahman H M, and et al. 2023 RSC Adv. 13(27) 18825–18853
5. Peng W, Pan Q, Ye J, Fang Y, and et al. 2023 Front. Oncol. 13 1120278
6. Lei F, Zheng Y and Li C 2022 J. Immigr. Minor. Health 24(2) 526–545
7. Leiter A, Veluswamy R R and Wisnivesky J P 2023 Nat. Rev. Clin. Oncol. 20(9) 624–639
8. Solassol I, Pinguet F and Quantin X 2019 Biomolecules 9(11) 668
9. Brooks M B 2013 The Oncologist 18(1) e3–e5
10. Moryl N, Obbens E A, Ozigbo O H, and Kris M G 2006 J. Support. Oncol. 4(3) 111
11. Gibson K H 1996 Quinazoline Derivatives (Patent WO9633980)
12. Peter G J and David M 2009 Process for the Preparation of 4- (3’chloro-4’-Fluoroanilino) -7-Methoxy-6- (3-Morpholinopropoxy) Quinazoline (Patent CN101348471)
13. Li Y, Yong Z, Ping G and et al. 2005 Chin. J. Med. Chem. 1 3
14. Savile C K, Colbeck J C, Huisman G W, and et al. 2010 Science 329(5989) 305–309
15. Huffman M A, Fryszkowska A, Campos K R, and et al. 2019 Science 366(6470) 1255–1259
16. Boucher D G, Nguyen Z A, Minteer S D, and et al. 2023 Angew. Chem. Int. Ed Engl. 2023 e202307780
17. Wu S and Shih J 2018 Mol. Cancer 17(1) 38
18. Saldaña-Rivera L, Bello M and Méndez-Luna D 2019 J. Biomol. Struct. Dyn. 37(17) 4671–4684
19. Wang S, Song Y and Liu D 2016 Front. Med. 10(4) 383–388
20. Gu X, Lin M, Fan C, and et al. 2019 Nano Lett. 19(5) 3344–3352
21. Șandor A, Oniga I, Oniga O, and et al. 2023 Pharmaceuticals 16(4) 534
22. Zhang, B Xu Z, Liu Q, and et al. 2021 Bioorganic Chem. 117 105420
23. Ding P N, Lord S J, Gebski, V and et al. 2017 J. Thorac. Oncol. 12(4) 633–643
24. Swaisland H C, Laight A, Ranson M, and et al. 2005 Clin. Pharmacokinet. 44(11) 1165–1177
25. Zhao C, Han S and Li P 2017 Curr. Drug Deliv. 14(2) 282–288
26. Brückl W, Tufman A and Huber R M 2017 Expert Rev. Anticancer Ther. 17(2) 143–155
27. Araghi M, Heidarnejad maleki A, Rostami S, and et al. 2023 Cancer Cell Int. 23 162
28. Cui J, Guo W, Wang C, and et al. 2007 J. Control Release Soc. 118(2) 204–215
29. Yoshimura M, Imamura F, Yamamoto S, and et al. 2004 Lung Cancer Amst. Neth. 45(1) 121–123
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-195-7
- ISBN (Online)
- 978-1-83558-196-4
- Published Date
- 04 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/16/20240517
- Copyright
- 04 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited